After the FDA slapped an updated safety warning on marketed oral JAK inhibitors for inflammatory diseases, market watchers have started worrying about other candidates in …
Some of Amgen’s key businesses are drawing concerns as competition looms. Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry …
Janssen-Cilag International NV (“Janssen”) presented a new analysis from VOYAGE 1 assessing efficacy responses based on absolute Psoriasis Area and Severity Index score (PASI), as …
Janssen Research & Development, LLC (Janssen) announced today longer-term results from a Phase 2 study investigating TREMFYA® (guselkumab), the first selective antiinterleukin- (IL)-23 monoclonal antibody …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
